Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 108,631 | 79,858 | 83,395 | 67,046 | 71,473 |
| Cost of Goods | 12,322 | 10,583 | 9,584 | 9,088 | 7,699 |
| Gross Profit | 96,309 | 69,275 | 73,811 | 57,958 | 63,774 |
| Operating Expenses | 96,748 | 86,400 | 74,314 | 68,973 | 67,627 |
| Operating Income | -117 | -16,542 | 81 | -10,927 | -3,154 |
| Other Income | 2,421 | 2,266 | 2,369 | 2,428 | 1,915 |
| Pre-tax Income | 2,304 | -14,276 | 2,450 | -8,499 | -1,239 |
| Income Tax | 6,212 | 3,428 | -22,787 | 5,356 | -16,211 |
| Net Income Continuous | -3,908 | -17,704 | 25,237 | -13,855 | 14,972 |
| Net Income | $-3,908 | $-17,704 | $25,237 | $-13,855 | $14,972 |
| EPS Basic Total Ops | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |
| EPS Basic Continuous Ops | -0.06 | -0.25 | 0.36 | -0.20 | 0.21 |
| EPS Diluted Total Ops | -0.06 | -0.25 | 0.37 | -0.20 | 0.21 |
| EPS Diluted Continuous Ops | -0.06 | -0.25 | 0.36 | -0.20 | 0.21 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.25 | 0.04 | N/A | N/A |
| EBITDA(a) | $313 | $-16,076 | $621 | $-10,324 | $-2,552 |